A clear plurality of GEN voters is predicting the best of success for the New York Genome Center (NYGC) when it comes to growing the city’s biotech cluster. In a recent poll, 43.1% said the center would succeed “a great deal,” compared with 27.5% who said the genome center would help Big Apple biocluster building “somewhat,” 23.5% said “not much,”  and the remaining were undecided. The $125 million NYGC, set to start operations in the spring, unites 11 academic medical centers, with the shared goal of developing one of North America’s largest genomics facilities. NYGC also hopes to close the longstanding gap in grant financing and infrastructure between New York and the nation’s top bioclusters, led by the San Francisco and Boston/Cambridge regions

Previous articlePfizer, Karo Bio Ally for Autoimmune Diseases
Next article2011’s Five Biggest Biopharma Acquisitions Provide Clues for What’s Ahead